March 2013- Volume 9, Issue 3

March 2013

In this Issue

Feature

A capitol idea -- AACR 2013 conference preview

A capitol idea -- AACR 2013 conference preview

AACR’s annual meeting in Washington, D.C., offers chance for education, networking and a public call for policy changes

A capitol idea -- AACR 2013 conference preview (Part 2)

A capitol idea -- AACR 2013 conference preview (Part 2)

More information about the annual meeting and more photos from Washington, D.C.

Research & Development

MAP leads to pot of gold

MAP leads to pot of gold

Allergan subsidiary, MAP Pharmaceuticals merger could be worth nearly $1 billion

Marriage for MS treatment

Marriage for MS treatment

Merck Serono and Opexa Therapeutics enter into $225 million drug development agreement

Canada continues stem cell tradition

Canada continues stem cell tradition

Toronto’s Stem Cell Therapeutics, Trillium propose merge to develop new drugs to combat AML, other cancers

Maxing out with GVAX

Maxing out with GVAX

Aduro acquires cancer vaccine assets from BioSante for $1 million

Safer drugs, better cancer care

Safer drugs, better cancer care

NanoSmart Pharmaceuticals and UCLA enter collaboration agreement for pediatric cancer drug development

Tools & Technology

End-to-end workflow

End-to-end workflow

Life Technologies acquires BAC, expands bioprocessing protein purification workflow

Dealing with the data

Dealing with the data

Curie- Cancer, GenoSplice to target cancer genomics data via bioinformatics

A P4 partnership

A P4 partnership

The Institute for Systems Biology and AB SCIEX partner to make medical care more ‘predictive, preventive, personalized and participatory’

Adding new dimensions

Adding new dimensions

Organovo and OHSU Knight Cancer Institute collaborate on biological models for cancer drug discovery and development

Global News

Uber-antibiotic duo

Uber-antibiotic duo

Sweden’s Pergamum collaborates with India’s Cadila Pharmaceuticals to develop novel peptides to treat infections

Addressing a growing need

Addressing a growing need

Galapagos acquires Cangenix for $1.5 million

European Lead Factory launched

European Lead Factory launched

Public-private partnership aims to accelerate early drug discovery

Resistance really is futile

Resistance really is futile

European partnership aims to re-enable antibiotics against resistant bacteria

A breakup worth billons

A breakup worth billons

Biogen Idec purchases Elan’s share in Tysabri franchise for more than $3 billion; Elan is already entertaining acquisition offers

Diagnostics

A deeper companionship

A deeper companionship

QIAGEN and Lilly enter into expanded collaboration relationship to develop and commercialize companion diagnostics

When East meets West

When East meets West

Vela, Jefferson to combine experience for the development of molecular diagnostic assays

Assay for AD

Assay for AD

Amorfix and QPS to collaborate on Alzheimer’s disease project

JPT Peptide, Institute for Medical Immunology partner on chronic fatigue syndrome

JPT Peptide, Institute for Medical Immunology partner on chronic fatigue syndrome

JPT Peptide Technologies GmbH, a wholly owned subsidiary of BioNTech AG, and the Institute for Medical Immunology at the Charité in Berlin recently announced a collaborative agreement to develop serological peptide markers for the differential diagnosis of chronic fatigue syndrome (CFS)

Omics & Systems Biology

Heart-smart commercialization

Heart-smart commercialization

Collaboration targets R&D of RNAi compound to treat cholesterol issues

It’s only logical

It’s only logical

King’s College London, Emerald Logic seek to develop predictive, discriminative Alzheimer’s model

Drawing a better map

Drawing a better map

New technique pinpoints protein locations, helping scientists figure out their functions in live cells

Glycomics on the map

Glycomics on the map

Kyowa Hakko Kirin to fund projects exploiting Ezose’s GlycanMap technology

Meddling with medulloblastoma

Meddling with medulloblastoma

Trio unites to seek metastasis biomarkers for common childhood brain tumors

Government Watch

The USPTO uncertainty principle

The USPTO uncertainty principle

Effects of changes in U.S. patent regime may take years to be fully understood, adjudicated

FDA on a hot streak

FDA on a hot streak

U.S. regulators approved a record number of new drugs in 2012

Taking it to the states

Taking it to the states

Pharmas and biotechs lobby state legislatures to limit generics, biosimilars

Commentary

A genome’s got to know its limitations

A genome’s got to know its limitations

Although we are believers in genomics, we suspect that it will take the conventional 20 years or so between investment in research and commercial exploitation. We also feel that application of genomics to healthcare delivery will take place by a large number of small steps, and not as a big bang. In short, a genome’s got to know its limitations.

Out of Order: Didn’t see that coming

Out of Order: Didn’t see that coming

Too often, the industry’s hands appear to be tied when it comes to providing target markets with information, as regulatory agencies and advertising counsels argue that consumers aren’t capable of digesting this information. I think we’re not giving today’s consumers enough credit.

Editor's Focus

Cancer patients: The heart of the matter

Cancer patients: The heart of the matter

If you’re in a position to create treatments for cancer, what’s the silver bullet for you? Is it creating a safe and effective blockbuster drug that brings in the revenue your company needs to continue work on future drugs? Is it an altruistic quest for a cure?

Special Reports

‘Good enough’ is no longer good enough

‘Good enough’ is no longer good enough

Trends in Cancer Research feature report Part 1 of 2: Aiming beyond the standard of care in oncology
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2022 Issue Front Cover

Latest Issue  

• Volume 18 • Issue 11 • November 2022

November 2022

November 2022